tradingkey.logo
tradingkey.logo
Search

Entera Bio Ltd

ENTX
Add to Watchlist
1.660USD
-0.030-1.78%
Close 07/02, 13:00ETQuotes delayed by 15 min
77.39MMarket Cap
LossP/E TTM

TradingKey Stock Score of Entera Bio Ltd

Currency: USD Updated: 2026-07-01

Key Insights

Entera Bio Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 157 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Entera Bio Ltd's Score

Industry at a Glance

Industry Ranking
157 / 387
Overall Ranking
290 / 4564
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive+

Entera Bio Ltd Highlights

StrengthsRisks
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Growing
The company is in a growing phase, with the latest annual income totaling USD 42.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 42.00K.
Fairly Valued
The company’s latest PE is -6.45, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 9.31M shares, decreasing 0.05% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 11.55K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 11.98.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
9.000
Target Price
+408.47%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Entera Bio Ltd?

The TradingKey Stock Score provides a comprehensive assessment of Entera Bio Ltd based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Entera Bio Ltd’s performance and outlook.

How do we generate the financial health score of Entera Bio Ltd?

To generate the financial health score of Entera Bio Ltd, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Entera Bio Ltd's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Entera Bio Ltd.

How do we generate the company valuation score of Entera Bio Ltd?

To generate the company valuation score of Entera Bio Ltd, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Entera Bio Ltd’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Entera Bio Ltd’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Entera Bio Ltd.

How do we generate the earnings forecast score of Entera Bio Ltd?

To calculate the earnings forecast score of Entera Bio Ltd, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Entera Bio Ltd’s future.

How do we generate the price momentum score of Entera Bio Ltd?

When generating the price momentum score for Entera Bio Ltd, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Entera Bio Ltd’s prices. A higher score indicates a more stable short-term price trend for Entera Bio Ltd.

How do we generate the institutional confidence score of Entera Bio Ltd?

To generate the institutional confidence score of Entera Bio Ltd, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Entera Bio Ltd’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Entera Bio Ltd.

How do we generate the risk management score of Entera Bio Ltd?

To assess the risk management score of Entera Bio Ltd, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Entera Bio Ltd’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Entera Bio Ltd.